Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. More Details
No risks detected for NEOG from our risk checks.
Flawless balance sheet with questionable track record.
Share Price & News
How has Neogen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEOG has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NEOG exceeded the US Medical Equipment industry which returned 19.1% over the past year.
Return vs Market: NEOG exceeded the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is Neogen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StNeogen Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
3 weeks ago | Simply Wall StWhat Do The Returns On Capital At Neogen (NASDAQ:NEOG) Tell Us?
Is Neogen undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NEOG ($78.25) is trading above our estimate of fair value ($27.7)
Significantly Below Fair Value: NEOG is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NEOG is poor value based on its PE Ratio (68x) compared to the US Medical Equipment industry average (49.6x).
PE vs Market: NEOG is poor value based on its PE Ratio (68x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: NEOG is poor value based on its PEG Ratio (6.2x)
Price to Book Ratio
PB vs Industry: NEOG is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (4x).
How is Neogen forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEOG's forecast earnings growth (11% per year) is above the savings rate (2.2%).
Earnings vs Market: NEOG's earnings (11% per year) are forecast to grow slower than the US market (22.1% per year).
High Growth Earnings: NEOG's earnings are forecast to grow, but not significantly.
Revenue vs Market: NEOG's revenue (6.4% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: NEOG's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NEOG's Return on Equity is forecast to be high in 3 years time
How has Neogen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEOG has high quality earnings.
Growing Profit Margin: NEOG's current net profit margins (14.2%) are lower than last year (14.3%).
Past Earnings Growth Analysis
Earnings Trend: NEOG's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: NEOG's earnings growth over the past year (1.8%) is below its 5-year average (12.9% per year).
Earnings vs Industry: NEOG earnings growth over the past year (1.8%) underperformed the Medical Equipment industry 1.8%.
Return on Equity
High ROE: NEOG's Return on Equity (8.1%) is considered low.
How is Neogen's financial position?
Financial Position Analysis
Short Term Liabilities: NEOG's short term assets ($556.7M) exceed its short term liabilities ($46.4M).
Long Term Liabilities: NEOG's short term assets ($556.7M) exceed its long term liabilities ($23.6M).
Debt to Equity History and Analysis
Debt Level: NEOG is debt free.
Reducing Debt: NEOG has not had any debt for past 5 years.
Debt Coverage: NEOG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NEOG has no debt, therefore coverage of interest payments is not a concern.
What is Neogen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEOG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEOG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEOG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEOG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEOG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Adent (52 yo)
Mr. John Edward Adent has been Chief Executive Officer at Neogen Corporation since July 17, 2017 and has been its President since September 22, 2017. He has been Director of Neogen Corporation since Octobe ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD2.12M) is below average for companies of similar size in the US market ($USD5.74M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|VP, CFO & Secretary||9.67yrs||US$902.84k||0.025% |
|Director of Corporate Communications||no data||no data||no data|
|VP & Chief Human Resources Officer||0.25yr||no data||no data|
|Chief Commercial Officer||0.083yr||no data||no data|
Experienced Management: NEOG's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
|Independent Director||26.92yrs||US$87.38k||0.061% |
|Director Emeritus||9.5yrs||US$13.56k||no data|
|Director Emeritus||no data||US$13.56k||no data|
|Independent Director||5.92yrs||US$88.38k||0.0032% |
|Independent Director||9.33yrs||US$88.38k||0.020% |
|Independent Chairman||0.42yr||US$90.88k||0.0038% |
|Independent Director||2.92yrs||US$87.88k||0% |
|Independent Director||3.92yrs||US$88.38k||0.010% |
Experienced Board: NEOG's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Neogen Corporation's company bio, employee growth, exchange listings and data sources
- Name: Neogen Corporation
- Ticker: NEOG
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$4.150b
- Shares outstanding: 53.04m
- Website: https://www.neogen.com
Number of Employees
- Neogen Corporation
- 620 Lesher Place
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NEOG||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 1989|
|NG2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 1989|
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safet ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/30 23:33|
|End of Day Share Price||2020/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.